BeOne Medicines (BEIGF) Short term Debt (2015 - 2026)

BeOne Medicines (BEIGF) has 11 years of Short term Debt data on file, last reported at $116.1 million in Q1 2026.

• Short term Debt for Q1 2026 came in at $116.1 million, down 84.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $116.1 million (down 84.79% YoY), and the FY2025 annual result was $57.3 million, down 93.27% from the prior year.
• Short term Debt rose to $116.1 million in Q1 2026 per BEIGF's latest filing, from $57.3 million in the prior quarter.
• Over five years, Short term Debt peaked at $863.8 million in Q3 2024 and troughed at $57.3 million in Q4 2025.
• A 5-year average of $556.4 million and a median of $564.8 million in 2022 frame the typical range for Short term Debt.
• The sharpest annual moves came in 2024 and 2025: Short term Debt jumped 193.45% in 2024, then sank 93.27% in 2025.
• A 5-year view of Short term Debt shows it stood at $441.3 million in 2022, then surged by 55.99% to $688.4 million in 2023, then rose by 23.7% to $851.5 million in 2024, then slumped by 93.27% to $57.3 million in 2025, then surged by 102.71% to $116.1 million in 2026.
• Business Quant data shows BEIGF's Short term Debt at $116.1 million in Q1 2026, $57.3 million in Q4 2025, and $813.3 million in Q3 2025.